LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE4 Homozygote AD

Overview

flowchart TD
    LX1001_Phase_1_2_Trial__NCT036["LX1001 Phase 1/2 Trial (NCT03634007) - Gene Ther"] -->|"references"| LDLR["LDLR"]
    LX1001_Phase_1_2_Trial__NCT036["LX1001 Phase 1/2 Trial (NCT03634007) - Gene Ther"] -->|"references"| LRP1["LRP1"]
    LX1001_Phase_1_2_Trial__NCT036["LX1001 Phase 1/2 Trial (NCT03634007) - Gene Ther"] -->|"references"| APOE["APOE"]
    style LX1001_Phase_1_2_Trial__NCT036 fill:#4fc3f7,stroke:#333,color:#000

This Phase 1/2 open-label, dose-escalation clinical trial evaluated the safety, tolerability, and preliminary efficacy of LX1001, an adeno-associated virus (AAV) serotype rh.10 gene therapy vector expressing human APOE2, in participants who are homozygous for the APOE4 allele and have been diagnosed with Alzheimer’s disease (AD). The study established the maximum tolerable dose across four ascending dose cohorts and generated initial evidence regarding APOE isoform conversion in the cerebrospinal fluid.

The trial ran from November 2019 to November 2024 and enrolled 15 participants across four dose levels. Participants completing the parent study were enrolled in the long-term follow-up study NCT05400330, which tracks safety and biomarker outcomes for up to 260 weeks post-administration.

Trial Details

Scientific Rationale

APOE4 Homozygosity as Highest Genetic Risk Factor

Homozygous APOE4 carriers represent the highest-risk population for Alzheimer’s disease^{1APOE genotypes modulate Alzheimer's disease beta-amyloid deposition2011 · JAMA Neurology · PMID 21911610Open reference}:

• APOE4/4 homozygotes have a 10-12× increased risk of AD compared to APOE3/3 carriers

• APOE4 homozygous prevalence: ~1-2% of the general population, but ~10-15% of all AD cases

• Earlier disease onset: APOE4/4 carriers develop AD symptoms approximately 5-10 years earlier than APOE3/3 carriers

• Mechanistic burden: APOE4 drives amyloid accumulation, tau pathology, neuroinflammation, BBB dysfunction, and impaired lipid transport

APOE2 Neuroprotection

The APOE2 isoform is associated with significantly reduced AD risk and multiple neuroprotective properties:

• Reduced AD risk: APOE2 carriers have ~40-50% lower risk of AD compared to APOE3/3

• Enhanced amyloid clearance: APOE2 efficiently promotes Aβ degradation and perivascular transport

• Improved synaptic integrity: Better support of dendritic spine maintenance and neuronal repair

• Anti-inflammatory: Reduced microglial activation and pro-inflammatory cytokine production

Gene Therapy Strategy

LX1001 delivers the APOE2 gene directly to the CNS via intrathecal AAVrh.10 administration, enabling persistent expression of APOE2 protein in the CSF and brain parenchyma. This approach:

1. Bypasses the blood-brain barrier delivery challenge

2. Achieves sustained therapeutic APOE2 levels not attainable with recombinant protein

3. Converts the APOE isoform profile from APOE4 toward APOE2-APOE4 (heterozygote)

4. Provides potential disease-modifying effects by addressing the upstream genetic risk

Intervention

LX1001 Gene Therapy Vector

Dose Cohorts

AAVrh.10 Serotype

The AAVrh.10 serotype was selected for^{2AAVrh.10 serotype for CNS gene therapy2017 · Human Gene Therapy · PMID 27852111Open reference}:

• High neuronal and glial transduction efficiency

• Lower prevalence of pre-existing neutralizing antibodies in human populations

• Efficient CNS penetration when delivered directly to CSF

• Established safety profile in prior gene therapy applications

Eligibility Criteria

Inclusion Criteria

1. Genetic status: APOE4 homozygotes (confirmed by genotyping)

2. Age: 50 years or older

3. Cognitive diagnosis: Mild cognitive impairment due to AD or mild-to-moderate dementia due to AD

4. CSF biomarkers: Evidence of AD-consistent CSF biomarkers (Aβ42, tau, p-tau)

5. AAV serology: Serum neutralizing anti-AAVrh10 titer <1:100

6. Infectious disease screen: No active hepatitis (A, B, or C) or HIV infection

7. Contraception: Fertile individuals must use barrier birth control for study duration

8. Washout: No experimental medications or protocols for at least 4 weeks prior to enrollment

9. Data privacy: Participants agree not to post study data on social media

Exclusion Criteria

1. Anti-amyloid therapies: Currently receiving or unable to wash out from monoclonal anti-amyloid therapy (aducanumab, lecanemab)

2. Anticoagulation: Unable to wash out from anti-coagulant medications

3. Spinal procedure contraindication: Does not fit American Journal of Neuroradiology recommendations for image-guided spinal procedures

4. Significant comorbidities: Malignancy, heart failure, liver or renal failure, HIV positive

5. Active infection: Elevated WBC, fever >38.5°C, infiltrate on chest X-ray

6. Prior gene/cell therapy: Prior or concurrent participation in any gene or cell therapy study

7. Imaging exclusions: >4 cerebral microhemorrhages, superficial siderosis, macrohemorrhage on screening MRI

8. MRI/PET/CSF inability: Cannot participate in required imaging or CSF collection procedures

9. Anesthesia contraindication: Cannot undergo procedures without general anesthesia (other than for gene therapy administration itself)

10. Hypersensitivity: Clinically significant hypersensitivity to study drug components (corticosteroids, proton-pump inhibitors)

11. Pregnancy/nursing: Pregnant or nursing

Outcome Measures

Primary Endpoints

Secondary Endpoints

The trial assessed multiple secondary endpoints including:

• APOE isoform conversion: CSF APOE isoform shift from APOE4 toward APOE2-APOE4 profile

• Amyloid PET: Florbetapir PET quantification of cerebral amyloid burden

• CSF biomarkers: Aβ42, Aβ42/Aβ40 ratio, total tau, phospho-tau

• Quantitative MRI: Volumetric analysis, white matter integrity

• Cognitive outcomes: ADAS-Cog, CDR-SB, and other standardized batteries

• Tau PET: Flortaucipir PET for tau pathology (primarily Cohorts 3 and 4)

Study Design

Screening Period (up to 42 days)
    ↓
Intrathecal LX1001 Administration (Day 0)
    ↓
Post-administration Follow-up (52 weeks per cohort)
    ↓
Safety monitoring: weeks 4, 8, 12, 26, 39, 52
CSF/blood biomarkers: weeks 4, 12, 26, 52
Amyloid PET: baseline and week 52
MRI: baseline and week 52
Cognitive assessments: baseline, weeks 26 and 52
    ↓
Completion → Enrollment in NCT05400330 (LTFU)

Dose Escalation Safety Review

Independent Safety Review Committee evaluated data after each cohort:

1. Review all adverse events and serious adverse events

2. Assess dose-limiting toxicities (DLTs)

3. Determine if escalation to next cohort is safe

4. Establish maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D)

Results and Findings

The trial was completed in November 2024. Top-line results have been reported:

• Safety profile: LX1001 demonstrated an acceptable safety profile across all dose cohorts

• APOE conversion: Evidence of APOE isoform conversion from APOE4 to APOE2-APOE4 in CSF

• Biomarker trends: Changes in CSF and imaging biomarkers consistent with biological activity

• Dosing: Fixed dose (Cohort 4) established as the recommended dose for further development

Detailed results will be published in peer-reviewed journals and presented at scientific conferences.

Mechanism of Action

APOE2 Expression Cascade

Following intrathecal administration, LX1001 transduces cells in the CNS, leading to sustained APOE2 protein expression:

Intrathecal AAVrh.10hAPOE2 administration
    ↓
Transduction of CNS cells (ependymal cells, meningeal cells, choroid plexus)
    ↓
Persistent APOE2 protein expression in CSF
    ↓
Isoform competition: APOE2 competes with endogenous APOE4 for lipid binding
    ↓
CSF APOE profile shifts from APOE4/APOE4 → APOE2/APOE4 heterozygote
    ↓
Neuroprotective effects across multiple pathways:
  • Enhanced amyloid clearance (microglial degradation + perivascular transport)
  • Reduced tau phosphorylation and aggregation
  • Improved synaptic function and neuronal repair
  • Decreased neuroinflammation
  • Preserved blood-brain barrier integrity
    ↓
Disease modification in APOE4 homozygotes

Key Molecular Mechanisms

APOE2 provides neuroprotection through^{3APOE2 neuroprotective mechanisms and gene therapy potential2023 · Neurobiology of Disease · PMID 36965941Open reference}:

1. Amyloid clearance: APOE2-Aβ complex is more efficiently cleared by microglial receptors (LDLR, LRP1)

2. Lipid transport: APOE2 supports neuronal lipid homeostasis, maintaining membrane integrity

3. Anti-inflammatory: Reduced NF-κB activation and microglial pro-inflammatory cytokine production

4. BBB protection: Preserved blood-brain barrier through pericyte and endothelial support

5. Tau modulation: Reduced kinase activity and enhanced phosphatase function

Clinical Significance

First Gene Therapy Targeting APOE4

LX1001 represents a groundbreaking approach as the first gene therapy to directly address the APOE4 genetic risk factor in AD:

• Upstream targeting: Addresses the fundamental genetic cause rather than downstream amyloid

• Persistent expression: Multi-year APOE2 expression vs. periodic antibody administration

• APOE4-specific: Direct mechanism targeting highest-risk patient population

• Disease-modifying potential: Could provide sustained disease modification

Comparison to Anti-Amyloid Antibodies

Future Development

The success of NCT03634007 supports continued development of LX1001:

1. Phase 2/3 efficacy trials in APOE4 homozygotes with early AD

2. Combination approaches with anti-amyloid or anti-tau therapeutics

3. Expansion to other APOE4-associated neurodegenerative conditions

4. Optimization of delivery and dosing regimens

Long-Term Follow-up

Participants completing this study are enrolled in NCT05400330, tracking:

• 5-year (260-week) safety profile

• Long-term biomarker trends (CSF APOE, amyloid PET, tau PET, MRI)

• Cognitive and clinical outcomes over extended follow-up

• Delayed adverse event monitoring

Cross-References

• APOE Gene and Alzheimer’s Risk

• APOE2 Neuroprotection

• APOE4 Homozygosity and Alzheimer’s

• Gene Therapy for Alzheimer’s Disease

• AAV Vector CNS Delivery

• Intrathecal Drug Delivery

• APOE and Lipid Metabolism

• LTFU Study: NCT05400330

• Alzheimer’s Disease Therapeutics

External Links

• ClinicalTrials.gov - NCT03634007

• ClinicalTrials.gov - NCT05400330 (LTFU)

• Lexeo Therapeutics Pipeline

• Alzheimer’s Drug Discovery Foundation

• Weill Cornell Medicine - Alzheimer’s Disease Research Unit